KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationInvestment in Debt & EquityLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Inovio Pharmaceuticals (INO) Accumulated Depreciation & Amortization (2016 - 2025)

Inovio Pharmaceuticals' Accumulated Depreciation & Amortization history spans 14 years, with the latest figure at $16.5 million for Q4 2024.

  • For Q4 2024, Accumulated Depreciation & Amortization fell 21.05% year-over-year to $16.5 million; the TTM value through Dec 2024 reached $16.5 million, down 21.05%, while the annual FY2024 figure was $16.5 million, 21.05% down from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2024 was $16.5 million at Inovio Pharmaceuticals, down from $20.9 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $21.6 million in Q4 2022 and bottomed at $89000.0 in Q4 2021.
  • The 5-year median for Accumulated Depreciation & Amortization is $16.5 million (2024), against an average of $11.8 million.
  • The largest annual shift saw Accumulated Depreciation & Amortization plummeted 55.5% in 2021 before it skyrocketed 24128.54% in 2022.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $200000.0 in 2020, then tumbled by 55.5% to $89000.0 in 2021, then surged by 24128.54% to $21.6 million in 2022, then decreased by 3.3% to $20.9 million in 2023, then decreased by 21.05% to $16.5 million in 2024.
  • Per Business Quant, the three most recent readings for INO's Accumulated Depreciation & Amortization are $16.5 million (Q4 2024), $20.9 million (Q4 2023), and $21.6 million (Q4 2022).